PROSPER: enzalutamide in men with non-metastatic castration-resistant prostate cancer
Enzalutamide delayed metastases by almost two years in men with rapidly rising PSA on hormone therapy and no visible spread, and longer follow-up showed it also lengthened survival.
Overview
Phase 3 placebo-controlled trial of 1,401 men with non-metastatic castration-resistant prostate cancer and PSA doubling time of ten months or less randomised 2:1 to enzalutamide or placebo with continued androgen deprivation.
Median metastasis-free survival was 36.6 versus 14.7 months (hazard ratio 0.29), and the final analysis showed median overall survival of 67.0 versus 56.3 months (hazard ratio 0.73); fatigue, hypertension and falls were more common.
- Median metastasis-free survival 36.6 vs 14.7 months; hazard ratio 0.29.
- Median overall survival 67.0 vs 56.3 months; hazard ratio 0.73.
Enzalutamide is one of three androgen receptor inhibitors standard for high-risk non-metastatic castration-resistant prostate cancer.
- Fatigue and cognitive effects are more prominent than with darolutamide.
- Conventional imaging defined non-metastatic status.
Similar pages
not linked directly; found by shared links- Key paperSPARTAN: apalutamide for non-metastatic castration-resistant prostate cancer
Shares Non-metastatic castration-resistant prostate cancer, New England Journal of Medicine.
- Key paperARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer
Shares Non-metastatic castration-resistant prostate cancer, New England Journal of Medicine.
- Key paperEMBARK: enzalutamide with or without leuprolide in high-risk biochemically recurrent prostate cancer
- TermDisease volume (CHAARTED high-volume versus low-volume) and LATITUDE risk
Shares Non-metastatic castration-resistant prostate cancer, Enzalutamide.
- TermPSA kinetics: PSA doubling time and PSA density
Shares Non-metastatic castration-resistant prostate cancer, Enzalutamide.
- TermmCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)
Shares Non-metastatic castration-resistant prostate cancer, Enzalutamide.
- CompanyAstellas
Shares PROSPER, Enzalutamide.